Research and Markets: Evolving Patterns and Unmet Needs in the TB Population in Developing and Developed Markets 2010-2020

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/4dc336/evolving_patterns) has announced the addition of Decision Resources, Inc.'s new report "Evolving Patterns and Unmet Needs in the TB Population in Developing and Developed Markets" to their offering.

The combination of animal-human transmission, opportunistic infection in AIDS patients, and rapid urbanization has led to sharp increases in tuberculosis (TB) cases in many parts of the world. Although the number of TB cases will decline over the coming decade as public health improves and the use of HAART (highly active antiretroviral therapy) becomes more widespread, TB will continue to be a public health concern and multidrug resistance a continuing problem in its treatment.

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan, Brazil, China, India, Russia, and South Africa.

Patient populations: Total number of diagnosed incident cases of active TB per year in each pharmaceutical market. The following subpopulations are also forecast: HIV-associated cases of TB, extrapulmonary cases of TB, multidrug-resistant cases of TB, and extensively drug-resistant cases of TB (in countries where extensively drug-resistant TB is a significant clinical entity).

Epidemiological forecast: The report forecasts all of the patient populations over the period 2010-2020. For China and India, patients are stratified by populations by urban or rural status to account for the different levels of risk and patterns of transmission in urban and rural populations, and the report considers how the ongoing urbanization of those countries will affect overall disease risk.

Medical practice: Systematic review and comparison of guidelines for the treatment of active TB in the countries considered in this report.

Drug resistance: Evaluation of both drug-resistant disease and drug toxicity as areas of unmet need, including our forecast of cases of multidrug-resistant and extensively drug-resistant TB over the period 2010-2020.

Companies Mentioned:

  • Akorn
  • Bayer/Merck
  • Chao Center
  • Johnson & Johnson
  • Pfizer

For more information visit http://www.researchandmarkets.com/research/4dc336/evolving_patterns

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716